Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

This is a Phase II, open-label, single-arm, multicenter study evaluating the safety and efficacy of combining Tislelizumab with induction chemoradiotherapy (CRT), followed by conversion surgery, in patients with locally advanced, unresectable esophageal squamous cell carcinoma (ESCC). Patients will receive induction CRT with weekly paclitaxel and cisplatin along with Tislelizumab, followed by two cycles of consolidation Tislelizumab-chemotherapy. If the tumor becomes resectable, patients will undergo surgery. The primary goal is to assess the 2-year overall survival (OS) rate. Secondary outc

Trial Details

NCT ID

NCT07039162

Phase

PHASE2

Sponsor

Ming-Yu Lien

Status

RECRUITING

Cancer Type

Esophageal Cancer

Interventions

Tislelizumab
Paclitaxel
Cisplatin
Radiation Therapy

Locations (sample)

Kaohsiung City, Taiwan|22.61626,120.31333
Kaohsiung City, Taiwan|22.61626,120.31333
Taichung, Taiwan|24.1469,120.6839
Taichung, Taiwan|24.1469,120.6839
Tainan, Taiwan|22.99259,120.20507

Key Eligibility Criteria

Patients had histologically confirmed, squamous-cell carcinoma of the esophagus
Clinical T4 cancer, at least one unresectable metastatic regional lymph node due to invasion into an adjacent organ, or computed tomographic (CT) e…
An age of at least 20 years
An Eastern Cooperative Oncology Group performance-status score 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →